Fair Value - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
Apr. 30, 2020	Sep. 30, 2020	Sep. 30, 2020
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Credit loss		$ 0	$ 0
Allowance for credit loss		$ 0	$ 0
Equity Securities [Member] \| Immunomedics Common Stock [Member]
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Proceeds from sale of investment	$ 174,700,000

Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 9
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-URI http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454

+ Details

Name:	us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense (reversal of expense) for expected credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), from change in present value of expected cash flows.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121558606&loc=SL82922868-210454

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 30
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=121582814&loc=SL82922897-210455

+ Details

Name:	us-gaap_DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow associated with the sale of securities classified as trading securities and held for investment purposes. Excludes proceeds from trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).

+ References

No definition available.

+ Details

Name:	us-gaap_ProceedsFromSaleOfTradingSecuritiesHeldforinvestment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=sgen_ImmunomedicsCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: